In a combinatorial regimen randomized phase-2 study of the PD-L1 inhibitor, atezolizumab, and the small molecule MEK-inhibitor, cobimetinib in 77 patients with PD-L1 positive cholangiocarcinoma, the combination met its primary endpoint with a median PFS 3.65 months versus 1.87 months in the atezolizumab cohort (46). The gene discussed is CD274; the disease is cholangiocarcinoma.